MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/cm9.0000000000003769

Медицинская библиотека · Chinese medical journal · 2025

Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial.

Zhao Yan, Wei Zhu, Feng Yanyan, Ma Lin, Jiao Danhong, Cui Yong, Gu Jun, Bian Kunpeng, Ci Chao, Zhu Jianjian, Lei Tiechi, Shi Yujie, Tao Xiaohua, Han Xiuping, Zhang Xiaoli, Zhang Litao, Li Ying, Chen Genhui, Zhang Jianzhong, study group

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Benvitimod (tapinarof), an aryl hydrocarbon receptor (AhR) agonist approved for treating plaque psoriasis, is being investigated as a potential treatment for atopic dermatitis (AD). The aim of this study was to evaluate the efficacy and safety of benvitimod 1% cream in patients aged 2 years or older with AD.

METHODS

This randomized controlled trial enrolled 271 Chinese patients with AD aged ≥2 years, who received either benvitimod 1% cream (n = 183) or vehicle cream (n = 88) twice daily for 8 weeks in a 2:1 ratio at 35 sites in China from June to November 2023. The primary endpoint was the proportion of patients achieving a 75% improvement in the Eczema Area and Severity Index (EASI) 75 at week 8. Secondary endpoints included achievement of Investigator's Global Assessment (IGA) scores of 0/1, 90% EASI improvement (EASI 90), and ≥3-point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS). Treatment-emergent adverse events (TEAEs) were monitored for safety evaluation. Furthermore, a subset of patients (n = 43) opted into a 44-week open-label extension.

RESULTS

At week 8, a significantly higher proportion of patients treated with benvitimod achieved EASI 75 compared to those receiving vehicle (54.4% [n = 183] vs. 25.5% [n = 88]; P <0.001). The benvitimod group also showed superior results across all secondary endpoints: IGA 0/1 (46.2% [n = 183] vs. 21.4% [n = 88]; P <0.001), EASI 90 (33.9% [58/171] vs. 13.5% [10/74]; P <0.001), and ≥3-point decrease in PP-NRS (54.0% [47/87] vs. 27.9% [12/43]; P <0.01). TEAEs occurred in 51.4% (94/183) of benvitimod-treated patients vs. 43.2% (38/88) of vehicle-treated patients, with most events being mild to moderate in severity.

CONCLUSION

Benvitimod 1% cream demonstrated favorable efficacy and safety in adult and pediatric patients with AD, supporting its potential as a novel topical treatment option.

TRIAL REGISTRATION: chinadrugtrials.org.cn, CTR20231413.

Для цитирования: Zhao Yan, Wei Zhu, Feng Yanyan, Ma Lin, Jiao Danhong, Cui Yong, Gu Jun, Bian Kunpeng, Ci Chao, Zhu Jianjian, Lei Tiechi, Shi Yujie, Tao Xiaohua, Han Xiuping, Zhang Xiaoli, Zhang Litao, Li Ying, Chen Genhui, Zhang Jianzhong, study group. Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial.. Chinese medical journal. 2025. DOI: 10.1097/cm9.0000000000003769.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.